Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.53 |
| ▸ | CA1 | P00915 | 8/20 | 0.49 |
| ▸ | CA2 | P00918 | 8/20 | 0.49 |
| ▸ | CA12 | O43570 | 6/20 | 0.49 |
| ▸ | CA7 | P43166 | 6/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24065052 | 1.00 | PNMT (0.53) | PNMTCA1CA2CA12CA7 | |
| SCHEMBL24065230 | 0.83 | CA1 (0.71) | PNMTCA1CA2CA12CA7 | |
| SCHEMBL15093571 | 0.81 | PNMT (0.40) | PNMTKDM1AHTR6 | |
| SCHEMBL24065006 | 0.80 | PNMT (0.52) | PNMTCA1CA2CA12CA7 | |
| SCHEMBL25086361 | 0.80 | PNMT (0.52) | PNMTCA1CA2CA12CA7 | |
| SCHEMBL12828069 | 0.79 | PNMT (0.51) | PNMTCA1CA2CA12CA7 | |
| SCHEMBL12828068 | 0.78 | PNMT (0.50) | PNMTCA1CA2CA12CA7 | |
| SCHEMBL19453942 | 0.78 | PNMT (0.57) | PNMT | |
| SCHEMBL24065198 | 0.75 | PNMT (0.48) | PNMTCA1CA2CA12CA7 | |
| SCHEMBL8688726 | 0.74 | DRD3 (0.62) | PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312229-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080312229-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| WO-2007065683-A1 | ARYL ACETIC ACID AND ESTER DERIVATIVES AND THEIR USES AS ANTIINFLAMMATORY | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312229-A1 | Organic Compounds | DRD4, DRD1, SLC10A6 | PNMT 864/4885CA1 3309/4885CA2 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.